Beyond GLP-1: Emerging targets and mechanisms for next-generation metabolic therapeutics.

Revolutionary research is uncovering new pathways that could transform diabetes and obesity treatment beyond current GLP-1 drugs. While GLP-1 agonists have revolutionized metabolic medicine, cutting-edge studies are revealing exciting alternatives including novel paracrine signaling pathways for insulin secretion, engineered weight-regulating hormones with enhanced stability, and optimized dual receptor targeting strategies. These breakthroughs were enabled by Revvity's comprehensive research platform - from immunoassays and high-content imaging system to cell analysis and detection instruments - supporting researchers in dissecting complex metabolic mechanisms and accelerating therapeutic discovery. Download our literature review to discover how our ecosystem can help you uncover the next breakthrough in diabetes and obesity therapeutics.

For research use only. Not for use in diagnostic procedures.